Presented at ESMO Immuno-Oncology (ESMO IO) Congress 2021
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Cecile Geuijen, Paul Tacken, Liang-Chuan Wang, Rinse Klooster, Pieter Fokko van Loo, Jing Zhou, Arpita Mondal, Yao-bin Liu, Arjen Kramer, Thomas Condamine, Alla Volgina, Linda J. A. Hendriks, Hans van der Maaden, Eric Rovers, Steef Engels, Floris Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwini Kulkarni, Wilfred Marissen, Cheng-Yen Huang, Leslie Hall, Shane Harvey, Soyeon Kim, Marina Martinez, Shaun O’Brien, Edmund Moon, Steven Albelda, Chrysi Kanellopoulou, Shaun Stewart, Horacio Nastri, Alexander B. H. Bakker, Peggy Scherle, Ton Logtenberg, Gregory Hollis, John de Kruif, Reid Huber, Patrick A. Mayes & Mark Throsby
Nature Communications volume 12, Article number: 4445 (2021)
MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells
Poster presented at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting.
MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models
Poster presented at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting.
An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties
Cecile A. Geuijen1, Paul Tacken1, Rinse Klooster1, Horacio Nastri2, Shaun Stewart2, Jing Zhou2, Steve Wang2, Cheng-Yen Huang2, Arjen Kramer1, Linda Kaldenberg-Hendriks1, John de Kruif1, Renate den Blanken-Smit1, Vanessa Zondag-van de Zande1, Abdul Basmeleh1, Willem Bartelink1, Patrick Mayes2, Gregory Hollis2, Reid Huber2, Mark Throsby1. 1Merus NV, Utrecht, Netherlands; 2Incyte Corporation, Wilmington, DE.
Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.
A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137
Patrick Mayes1, Paul Tacken2, Steve Wang1, Pieter-Fokko van Loo2, Thomas Condamine1, Hans van der Maaden2, Eric Rovers2, Steef Engels2, Floris Fransen2, Ashwini Kulkarni1, Yao-bin Liu1, Arpita Mondal1, Leslie Hall1, Soyeon Kim3, Marina Martinez3, Shaun O’Brien3, Edmund Moon3, Steven Albelda3, Peggy Scherle1, Gregory Hollis1, Reid Huber1, Mark Throsby2, Cecile A. Geuijen2. 1Incyte Corporation, Wilmington, DE; 2Merus NV, Utrecht, Netherlands; 3University of Pennsylvania, Philadelphia.
Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.